EP3600430A4 - Conjugué de folate destiné à être utilisé dans le ciblage de macrophages associés à une tumeur - Google Patents

Conjugué de folate destiné à être utilisé dans le ciblage de macrophages associés à une tumeur Download PDF

Info

Publication number
EP3600430A4
EP3600430A4 EP17903862.5A EP17903862A EP3600430A4 EP 3600430 A4 EP3600430 A4 EP 3600430A4 EP 17903862 A EP17903862 A EP 17903862A EP 3600430 A4 EP3600430 A4 EP 3600430A4
Authority
EP
European Patent Office
Prior art keywords
tumor associated
associated macrophages
targeting tumor
folate conjugate
folate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17903862.5A
Other languages
German (de)
English (en)
Other versions
EP3600430A1 (fr
Inventor
Iontcho Radoslavov Vlahov
Christopher Paul Leamon
Longwu Qi
Ning Zou
Kevin Yu Wang
Albert E. FELTEN
Garth L. Parham
Fei You
Hari Krishna R. Santhapuram
Spencer J. HAHN
Joseph Anand Reddy
Yingjuan J. LU
II Leroy W. WHEELER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endocyte Inc
Original Assignee
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2017/024770 external-priority patent/WO2017172930A1/fr
Application filed by Endocyte Inc filed Critical Endocyte Inc
Publication of EP3600430A1 publication Critical patent/EP3600430A1/fr
Publication of EP3600430A4 publication Critical patent/EP3600430A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP17903862.5A 2016-03-29 2017-09-14 Conjugué de folate destiné à être utilisé dans le ciblage de macrophages associés à une tumeur Withdrawn EP3600430A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662314688P 2016-03-29 2016-03-29
US201662323282P 2016-04-15 2016-04-15
US201662396409P 2016-09-19 2016-09-19
PCT/US2017/024770 WO2017172930A1 (fr) 2016-03-29 2017-03-29 Conjugués de pbd pour le traitement de maladies
PCT/US2017/051662 WO2018182776A1 (fr) 2016-03-29 2017-09-14 Conjugué de folate destiné à être utilisé dans le ciblage de macrophages associés à une tumeur

Publications (2)

Publication Number Publication Date
EP3600430A1 EP3600430A1 (fr) 2020-02-05
EP3600430A4 true EP3600430A4 (fr) 2020-12-30

Family

ID=69140942

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17903862.5A Withdrawn EP3600430A4 (fr) 2016-03-29 2017-09-14 Conjugué de folate destiné à être utilisé dans le ciblage de macrophages associés à une tumeur

Country Status (3)

Country Link
EP (1) EP3600430A4 (fr)
CN (1) CN110678204A (fr)
WO (1) WO2018182776A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112791192B (zh) * 2020-12-31 2023-04-07 上海交通大学 炎性细胞靶向蜂毒素脂质体纳米制剂及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014062697A2 (fr) * 2012-10-16 2014-04-24 Endocyte, Inc. Conjugués d'administration de médicament contenant des acides aminés artificiels et procédés d'utilisation
WO2016085967A1 (fr) * 2014-11-25 2016-06-02 Endocyte, Inc. Procédés de traitement du cancer par ciblage de macrophages associés à une tumeur
WO2017172930A1 (fr) * 2016-03-29 2017-10-05 Endocyte, Inc. Conjugués de pbd pour le traitement de maladies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1592457T3 (da) * 2003-01-27 2012-10-22 Endocyte Inc Folat-vinblastin-konjugat som lægemiddel
JP5690589B2 (ja) * 2007-06-25 2015-03-25 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 親水性スペーサーリンカーを含有する結合体
EP2349274A4 (fr) * 2008-09-17 2014-12-17 Endocyte Inc Conjugués d'antifolates liant le récepteur de folate
JP2013501224A (ja) * 2009-07-31 2013-01-10 エンドサイト，インク． 葉酸を標的とした診断及び処置

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014062697A2 (fr) * 2012-10-16 2014-04-24 Endocyte, Inc. Conjugués d'administration de médicament contenant des acides aminés artificiels et procédés d'utilisation
WO2016085967A1 (fr) * 2014-11-25 2016-06-02 Endocyte, Inc. Procédés de traitement du cancer par ciblage de macrophages associés à une tumeur
WO2017172930A1 (fr) * 2016-03-29 2017-10-05 Endocyte, Inc. Conjugués de pbd pour le traitement de maladies

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHRISTOPHER P. LEAMON ET AL: "Folate-Vinca Alkaloid Conjugates for Cancer Therapy: A Structure-Activity Relationship", BIOCONJUGATE CHEMISTRY, vol. 25, no. 3, 19 March 2014 (2014-03-19), pages 560 - 568, XP055749294, ISSN: 1043-1802, DOI: 10.1021/bc400441s *
JOSEPH A. REDDY ET AL: "Pre-clinical studies of EC2629, a highly potent folate- receptor-targeted DNA crosslinking agent", SCIENTIFIC REPORTS, vol. 10, no. 1, 29 July 2020 (2020-07-29), XP055749599, DOI: 10.1038/s41598-020-69682-9 *
See also references of WO2018182776A1 *
YINGJUAN LU ET AL: "Antiinflammatory Activity of a Novel Folic Acid Targeted Conjugate of the mTOR Inhibitor Everolimus", MOLECULAR MEDICINE, vol. 21, no. 1, 1 January 2015 (2015-01-01), WASHINGTON, DC; US, pages 584 - 596, XP055749288, ISSN: 1076-1551, DOI: 10.2119/molmed.2015.00040 *

Also Published As

Publication number Publication date
EP3600430A1 (fr) 2020-02-05
WO2018182776A1 (fr) 2018-10-04
CN110678204A (zh) 2020-01-10

Similar Documents

Publication Publication Date Title
IL265919B (en) Pyrrolobenzodiazepine conjugates
HK1231367A1 (zh) 抗體藥物偶聯物、試劑和製備方法及其治療用途
EP3473270A4 (fr) Conjugué anticorps-médicament
EP3307749A4 (fr) Lieurs hydrophiles pour conjugaison
GB201607478D0 (en) Pyrrolobenzodiazepine Conjugates
EP3107557A4 (fr) Conjugués anticorps-médicament hydrophiles
EP3207162A4 (fr) Polythérapie destinée à être utilisée en cancérothérapie
ZA201805526B (en) Pyrrolobenzodiazepine conjugates
IL269945B (en) Conjugates of pyrrolobenzodiazepine
EP3501548A4 (fr) Conjugué anticorps-médicament ciblant le facteur tissulaire
IL272625B1 (en) Conjugates of pyrrolobenzodiazepine
EP3261678B8 (fr) Conjugués anticorps-uréase pour des fins thérapeutiques
GB201602363D0 (en) Pyrrolobenzodiazepine conjugates
GB201602359D0 (en) Pyrrolobenzodiazepine Conjugates
EP3532638A4 (fr) Ciblage de microarn-101-3 p dans une cancérothérapie
GB201619490D0 (en) Pyrrolobenzodiazepine conjugates
EP3600430A4 (fr) Conjugué de folate destiné à être utilisé dans le ciblage de macrophages associés à une tumeur
EP3665302A4 (fr) Associations de médicaments pour le ciblage de multiples mutations dans le cancer
GB201721337D0 (en) Pyrrolobenzodiazepine conjugates
GB201706133D0 (en) Pyrrolobenzodiazepine conjugates
GB201607485D0 (en) Pyrrolobenzodiazepine Conjugates
GB201607488D0 (en) Pyrrolobenzodiazepine Conjugates
GB201602360D0 (en) Pyrrolobenzodiazepine conjugates

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191025

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LEAMON, CHRISTOPHER PAUL

Inventor name: WANG, KEVIN YU

Inventor name: ZOU, NING

Inventor name: FELTEN, ALBERT E.

Inventor name: QI, LONGWU

Inventor name: PARHAM, GARTH L.

Inventor name: REDDY, JOSEPH ANAND

Inventor name: YOU, FEI

Inventor name: VLAHOV, IONTCHO RADOSLAVOV

Inventor name: HAHN, SPENCER J.

Inventor name: WHEELER, II, LEROY W.

Inventor name: LU, YINGJUAN J.

Inventor name: SANTHAPURAM, HARI KRISHNA R.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: FELTEN, ALBERT E.

Inventor name: PARHAM, GARTH L.

Inventor name: WHEELER, II, LEROY W.

Inventor name: LU, YINGJUAN J.

Inventor name: WANG, KEVIN YU

Inventor name: SANTHAPURAM, HARI KRISHNA R.

Inventor name: HAHN, SPENCER J.

Inventor name: VLAHOV, IONTCHO RADOSLAVOV

Inventor name: ZOU, NING

Inventor name: LEAMON, CHRISTOPHER PAUL

Inventor name: QI, LONGWU

Inventor name: YOU, FEI

Inventor name: REDDY, JOSEPH ANAND

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40023923

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20201130

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/55 20170101AFI20201124BHEP

Ipc: A61P 35/00 20060101ALI20201124BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20210629